A Business at a Glance
0 of 5 daily views used (5 remaining). Sign up free for 10 daily views, or try AAPL for a full preview.
Ocugen is aiming to redefine the future of vision through game-changing gene therapies with the potential to address significant, unmet medical needs. Our First-in-class, breakthrough modifier gene therapy platform presents a potential paradigm shift in treating inherited retinal diseases and blindness diseases affecting millions across the globe. Our technology pipeline includes: Novel Modifier Gene Therapy Platform — •OCU400- Based on the use of nuclear hormone receptors ("NHRs"), we believe our novel modifier gene therapy platform has the potential to address major blindness diseases, including rare genetic diseases such as RP (OCU400), with a gene-agnostic approach. OCU400 is intended for early to advanced cases of RP including clinical and/or genetic diagnosis with both syndromic and non-syndromic forms of the disease. In January 2025, we announced positive two-year data for multiple mutations from the Phase 1/2 clinical trial for OCU400.
| Metric | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|---|
| Revenue | 0 | - | - | - | - | 0 |
| Net Income | -68M | -68M | -54M | -63M | -87M | -58M |
| EPS | $-0.23 | $-0.23 | $-0.80 | $-0.26 | $-0.40 | $-0.30 |
| Free Cash Flow | -57M | -57M | -46M | -73M | -65M | -49M |
| ROIC | -114.2% | -114.2% | -94.9% | -80.2% | -64.8% | -62.8% |
| Gross Margin | - | - | - | - | - | - |
| Debt/Equity | 0.00 | -2.47 | 1.01 | 0.07 | 0.03 | 0.02 |
| Dividends/Share | $0.00 | - | - | - | - | - |
| Operating Income | -63M | -63M | -55M | -66M | -89M | -58M |
| Operating Margin | 0.0% | - | - | - | - | - |
| ROE | 0.0% | -776.9% | -182.4% | -155.5% | -105.1% | -103.5% |
| Shares Outstanding | 295M | 295M | 328M | 243M | 217M | 195M |
Ocugen, Inc. passes 0 of 9 quality checks, indicating weak fundamentals.
Ocugen, Inc. (OCGN) has a 5-year average return on invested capital (ROIC) of -83.4%. This is below average and may indicate limited pricing power.
Ocugen, Inc. (OCGN) has a market capitalization of $531M. It is classified as a small-cap stock.
Ocugen, Inc. (OCGN) does not currently pay a regular dividend.
Ocugen, Inc. (OCGN) operates in the Biological Products, (No Diagnostic Substances) industry, within the Healthcare sector.
Ocugen, Inc. (OCGN) generated $-57 million in free cash flow in its most recent fiscal year. Negative free cash flow may indicate heavy investment or operational challenges.
Ocugen, Inc. (OCGN) reported earnings per share (EPS) of $-0.23 in its most recent fiscal year.
Ocugen, Inc. (OCGN) has a return on equity (ROE) of -776.9%. A negative ROE may indicate losses or negative equity.
The Ledger Terminal provides 12 years of financial data for Ocugen, Inc. (OCGN), sourced directly from SEC EDGAR filings. This includes income statements, balance sheets, cash flow statements, and key financial ratios.
Ocugen, Inc. (OCGN) has a book value per share of $-0.04, based on its most recent annual SEC filing.